Herceptin (Trastuzumab) for Breast Cancer Treatment
Herceptin (Trastuzumab) for Breast Cancer Treatment: Quick Links
Important Safety Information
Adjuvant Breast Cancer
Metastatic Breast Cancer
Full Prescribing Information
Switch to Healthcare Professionals
Share your Herceptin Story
Herceptin (Trastuzumab) and Breast Cancer: Patients and Caregivers
This site is intended for US Residents only. If you are not a US Resident, please click here.
Herceptin (Trastuzumab) Go to Patient and Caregiver Site Herceptin (Trastuzumab): Go to Healthcare Professional Site English  |   Español
Search this site: Text Size: Herceptin (Trastuzumab) for Breast Cancer Treatment: Increase Font Size Herceptin (Trastuzumab) for Breast Cancer Treatment: Decrease Font Size Herceptin (Trastuzumab) for Breast Cancer Treatment: Print Page Print Page Herceptin (Trastuzumab) for Breast Cancer Treatment: Email Page E-Mail Page
Herceptin (Trastuzumab) Breast Cancer: Foundation

HER2 Testing Information | What Your Test Results Mean

Breast Cancer Test Results

To classify exactly what kind of breast cancer you have, your doctor may take a biopsy of your tumor, which is a sample taken from the tumor either during surgery or using a needle. That sample tissue is then studied in a lab to determine exactly what kind of tumor it is. Tests are done to look for different substances in the tumor, and each test result is assigned a status, such as positive or negative. The results are called your pathology report.

Knowing the biological makeup of the tumor helps the doctor understand how quickly the cancer might grow and what treatments may be best.

For breast cancer, a doctor wants to know a cancer's hormone receptor status and HER2 status. Hormones such as estrogen and progesterone play a role in many breast cancers, and it is important to know whether a tumor is positive or negative for either of these hormone receptors. An estrogen-receptor-positive tumor is called "ER+", and a progesterone-receptor-positive tumor is called "PR+". Tumors that are positive for either of these hormone receptors may benefit from hormonal therapy.

Similarly, HER2 status can tell a lot about how aggressive the breast cancer is, as well as what treatments may provide the most benefit. HER2 status and hormone-receptor status are not the same thing, and being positive for one does not mean the cancer is positive for the other. Again, knowing what kind of cancer you have is critical to deciding what the best course of treatment will be.

Accurate testing is important; your pathology report may contain inconclusive results. Sometimes one test may not be enough to determine with certainty whether your tumor is HER2+. Ask your doctor to discuss the results of your pathology report, explain how your tumor's HER2 status was determined, and to let you know whether another test may be necessary.

Herceptin (Trastuzumab) Advanced Breast Cancer Treatment: Print Page
Herceptin (Trastuzumab) for Breast Cancer Treatment: Privacy Policy Herceptin (Trastuzumab) for Breast Cancer Treatment: Terms and Conditions Herceptin (Trastuzumab) for Breast Cancer Treatment: Prescribing Information Herceptin (Trastuzumab) for Breast Cancer Treatment: Safety Information Herceptin (Trastuzumab) for Breast Cancer Treatment: Site Map Herceptin (Trastuzumab) for Breast Cancer Treatment: Contact Information
Genentech BioOncology © 2008 Genentech, Inc. All rights reserved. This site intended for US residents only.